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Omega-3 Long Chain Polyunsaturated Fatty
Acids to Prevent Preterm Birth
A Systematic Review and Meta-analysis
Gabriele Saccone, MD, and Vincenzo Berghella, MD
OBJECTIVE: To evaluate the efficacy of omega-3 in
reducing the incidence of preterm birth.
DATA SOURCES: Searches were performed in MED-
LINE, OVID, Scopus, ClinicalTrials.gov, the PROSPERO
International Prospective Register of Systematic Reviews,
EMBASE, and the Cochrane Central Register of Con-
trolled Trials with the use of a combination of keywords
related to “fish oil,” “pregnancy,” and “omega-3.”
METHODS OF STUDY SELECTION: We included all
randomized controlled trials of asymptomatic women
with singleton gestations who were randomized to pro-
phylactic treatment with either omega-3 supplementa-
tion or control (either placebo or no treatment).
Exclusion criteria included trials in women with multiple
gestations, intrauterine growth restriction, gestational
hypertension or preeclampsia at randomization, prior
preterm birth, and trials with polyunsaturated fatty acids
as control.
TABULATION, INTEGRATION, AND RESULTS: Nine
randomized trials including 3,854 eligible women were
identified. Women who received omega-3 had a similar
rate of preterm birth before 37 weeks of gestation
compared with women in the control group (7.7%
compared with 9.1%, respectively; relative risk 0.90,
95% confidence interval [CI] 0.72–1.11). There were no
significant differences in birth weight, neonatal intensive
care unit admission, necrotizing enterocolitis, sepsis, or
perinatal death in the omega-3 compared with control
groups, respectively. There were no significant differen-
ces in the subgroup analyses, except for the rate of
perinatal death, which was lower (0.3% compared with
1.2%; relative risk 0.27, 95% CI 0.09–0.80) in the women
who received omega-3 before 21 weeks of gestation
and in trials with low risk of bias (0.3% compared with
1.0%; relative risk 0.28, 95% CI 0.09–0.89) compared
with women in the control group. However, in no
randomized controlled trial was perinatal death the
primary outcome.
CONCLUSION: Omega-3 supplementation during
pregnancy does not reduce the incidence of preterm
birth or improve neonatal outcome.
(Obstet Gynecol 2015;125:663–72)
DOI: 10.1097/AOG.0000000000000668
In 1986, an epidemiologic study from the FaeroeIslands first suggested that a high intake of foods
rich in omega-3 may increase birth weights by pro-
longing gestation.1 Preterm birth remains the number
one cause of perinatal mortality in many countries,
including the United States.2 Prior preterm birth is
one of the most important risk factors for preterm
birth.3 However, most preterm births occur in women
without a prior preterm birth. Randomized controlled
trials have been performed to assess if omega-3
supplementation may prevent preterm birth with
contradicting results.4–12 So far, the efficacy of
omega-3 in reducing the incidence of preterm birth
is still unclear.
The aim of this meta-analysis was to evaluate the
efficacy of omega-3 in reducing the incidence of
preterm birth in asymptomatic singleton gestations
without prior preterm birth.
SOURCES
The research protocol was designed a priori, defining
methods for searching the literature, including and
examining articles, and extracting and analyzing data.
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Searches were performed in MEDLINE, OVID,
Scopus, ClinicalTrials.gov, the PROSPERO Interna-
tional Prospective Register of Systematic Reviews,
EMBASE, and the Cochrane Central Register of Con-
trolled Trials with the use of a combination of key-
words and text words related to “fish oil,” “long chain
polyunsaturated fatty acids,” “pregnancy,” and
“omega-3” from inception of each database to August
2014. No restrictions for language or geographic loca-
tion were applied.
STUDY SELECTION
We included all randomized controlled trials (RCTs)
of asymptomatic singleton gestations who were ran-
domized to prophylactic treatment with either omega-3
supplementation or control (either placebo or no
treatment). All published randomized studies on
omega-3 supplementation during pregnancy were
carefully reviewed.
Only trials that enrolled women carrying single-
ton gestations without prior preterm birth were
included. Exclusion criteria included quasirandom-
ized trials (ie, trials in which allocation was done on
the basis of a pseudorandom sequence, eg, odd and
even hospital number or date of birth, alternation),
trials in women with multiple gestations, intrauterine
growth restriction or gestational hypertension or pre-
eclampsia at randomization, prior preterm birth, trials
with either only biochemical outcomes or no infor-
mative outcomes, trials with polyunsaturated fatty
acids (PUFAs) as control, and trials with PUFAs
treatment other than omega-3.
Before data extraction, the review was registered
with the PROSPERO International Prospective Reg-
ister of Systematic Reviews (registration No.
CRD42014013752). The meta-analysis was per-
formed following the Preferred Reporting Item for
Systematic Reviews and Meta-analyses statement.13
Data abstraction was completed by two indepen-
dent investigators (G.S., V.B.). Each investigator
independently abstracted data from each study and
analyzed data separately. Differences were reviewed
and further resolved by common review of the entire
data. Data abstracted included number of study
patients, number of patients in intervention and
control groups, type, route and dosage of interven-
tion and control, gestational age at randomization,
gestational age at delivery, interval from randomiza-
tion to delivery (ie, latency), obstetric complications,
and neonatal outcome including birth weight, admis-
sion to neonatal intensive care unit, neonatal
respiratory distress syndrome, bronchopulmonary
dysplasia, intraventricular hemorrhage, necrotizing
enterocolitis, neonatal sepsis, and perinatal death.
For studies that did not stratify data, composite data
were extracted. When possible, authors were con-
tacted for missing data.
The risk of bias in each included study was
assessed by using the criteria outlined in the Co-
chrane Handbook for Systematic Reviews of Inter-
ventions.14 Seven domains related to risk of bias
were assessed in each included trial because there
is evidence that these issues are associated with
biased estimates of treatment effect: 1) random
sequence generation, 2) allocation concealment, 3)
blinding of participants and personnel, 4) blinding
of outcome assessment, 5) incomplete outcome data,
6) selective reporting, and 7) other bias. Review au-
thors’ judgments were categorized as “low risk,”
“high risk,” or “unclear risk” of bias.14
All analyses were done using an intention-to-treat
approach, evaluating women according to the treat-
ment group to which they were randomly allocated in
the original trials. The primary outcome included
preterm birth before 37 weeks of gestation. Secondary
outcomes included preterm birth before 34 weeks of
gestation, spontaneous preterm birth before 37 weeks
of gestation, spontaneous preterm birth before 34
weeks of gestation, gestational age at delivery, latency,
preterm premature rupture of membranes, and
neonatal outcome including birth weight, neonatal
intensive care unit, respiratory distress syndrome,
bronchopulmonary dysplasia, intraventricular hemor-
rhage, necrotizing enterocolitis, neonatal sepsis, and
perinatal death (defined as the sum of stillbirth and
neonatal death).
We planned subgroup analyses in women who
received daily both eicosapentaenoic acid and dehy-
droacetic acid, by randomization before or after 21
weeks of gestation and by low compared with other
than low risk of bias in all items according to
Cochrane Collaboration’s tool.14
The data analysis was completed independently
by the authors using Review Manager 5.3. The
completed analyses were then compared, and any
difference was resolved with review of the entire data
and independent analysis. Statistical heterogeneity
between studies was assessed using the Cochrane Q
statistic and Higgins I2 statistics. In case of statistical
significant heterogeneity (P value of the Cochrane
Q statistic ,.1), the random effects model of
DerSimonian and Laird was used to obtain the pooled
relative risk estimate; otherwise, a fixed effect model
was planned. The summary measures were reported
as risk ratio (RR) with 95% confidence interval (CI).
P value ,.05 was considered statistically significant.
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RESULTS
We initially identified 29 trials on omega-3 supple-
mentation during pregnancy.4–12,15–34 No similar sys-
tematic reviews were found during the search process.
Twenty RCTs were excluded for various reasons.15–34
(Box 1).
Nine trials that met inclusion criteria for this
meta-analysis were analyzed.4–12 Figure 1 shows the
flow diagram (Preferred Reporting Item for System-
atic Reviews and Meta-analyses template) of informa-
tion through the different phases of the review (Fig. 1).
The quality of RCTs included in our meta-
analysis was assessed by the Cochrane Collabora-
tion’s tool14 (Fig. 2). Most studies had a low risk of bias
in allocation concealment, blinding, and selective re-
porting. Figure 3 shows the funnel plot for assessing
publication bias for preterm birth before 37 weeks of
gestation.
The characteristics of the nine included trials are
summarized in Table 1. Eight studies used placebo as
a control. Of the 3,854 included women, 1,868
(48.5%) were randomized to the omega-3 group and
1,986 (51.5%) to the control group. Six studies used
eicosapentaenoic acid and docosahexaenoic acid
together as treatment, whereas the other three used
only docosahexaenoic acid (Table 1). None of the
studies had preterm birth as primary outcome.
Table 2 shows extracted data and selective out-
comes of included trials. Women randomized to the
intervention group had the same mean age as the
control group. The mean of gestational age at ran-
domization was approximately 23 weeks in both
groups. Furthermore, we found no differences in ges-
tational age at delivery (mean difference 0.57 days,
95% CI 20.62 to 1.76) or in latency (mean difference
0.83 days, 95% CI 20.86 to 2.52) between the two
groups (Table 2).
Women who received omega-3 supplementation
had a similar rate of preterm birth before 37 weeks of
gestation compared with women in the control group
(7.7% compared with 9.1%, respectively; RR 0.90,
95% CI 0.72–1.11) (Table 3; Fig. 4). We found no
significant differences in neonatal birth weight (mean
difference 27.76 g, 95% CI 227.49 to 83.02), neonatal
intensive care unit (0% compared with 6.9%; RR 0.19,
95% CI 0.01–3.75), necrotizing enterocolitis (0.8%
compared with 0%; RR 2.98, 95% CI 0.12–73.13),
sepsis (0.25% compared with 0.17%; RR 6.96, 95%
CI 0.36–134.57), or perinatal death (1.0% compared
Box 1. List of Excluded Studies (n520)
Twin gestations31: 1
Women with preeclampsia29: 1
Women with prior preterm birth23: 1
Only biochemical outcomes available15–17,19,20,24,27,33: 8
Linoleic or linolenic acids were used as treatment25,26: 2
Polyunsaturated fatty acids as control21,22,30,34: 4
Duplicate18: 1
Only on term-born neonates32: 1
No maternal characteristics available28: 1
Total randomized controlled trials excluded: 20
Data are n.
Fig. 1. Flow diagram of studies identified in the systematic
review (Preferred Reporting Item for Systematic Reviews
and Meta-Analyses [PRISMA] template).
Saccone. Omega-3 for Prevention of Preterm Birth. Obstet Gynecol
2015.
VOL. 125, NO. 3, MARCH 2015 Saccone and Berghella Omega-3 for Prevention of Preterm Birth 665
Copyright ª by The American College of Obstetricians
and Gynecologists. Published by Wolters Kluwer Health, Inc.
Unauthorized reproduction of this article is prohibited.
with 1.8%; RR 0.61, 95% CI 0.30–1.24) (Fig. 5) in the
omega-3 compared with control groups, respectively
(Table 3). No data were available about preterm birth
before 34 weeks of gestation, spontaneous preterm
birth before 37 weeks of gestation, spontaneous pre-
term birth at less than 34 weeks of gestation, preterm
premature rupture of membranes, respiratory distress
syndrome, bronchopulmonary dysplasia, or intraven-
tricular hemorrhage.
We found in general no significant differences in
the subgroup analyses in the outcomes with data
available (Tables 4, 5, and 6), except for few signifi-
cant results favoring omega-3 supplementation. In
women who received both eicosapentaenoic acid
and docosahexaenoic acid, birth weight was higher
(mean difference 51.18 g, 95% CI 12.33–90.03) com-
pared with neonates in the control group. In the
women who received omega-3 before 21 weeks of
gestation, the rate of perinatal death was lower in
the omega-3 group compared with those in the con-
trol group (0.3% compared with 1.2%; RR 0.27, 95%
CI 0.09–0.80) (Table 5). In the studies with low risk of
bias, birth weight was higher (mean difference 60.66
g, 95% CI 19.78–101.54) and the rate of perinatal
death lower (0.3% compared with 1.0%; RR 0.28,
95% CI 0.09–0.89) in women who received omega-3
compared with women in the control group (Table 6).
DISCUSSION
This meta-analysis of the nine RCTs evaluating the
efficacy of omega-3 supplementation in 3,854 asymp-
tomatic singleton gestations without prior preterm birth
shows that omega-3 supplementation is not associated
either with significant prevention of preterm birth nor
with improved neonatal outcomes. A significant
decrease in perinatal death, which was consistently
defined in the pertinent trials as the sum of stillbirth
and neonatal death, was found in the planned subgroup
Fig. 2. Assessment of risk of bias. A. Summary of risk of bias for each trial. +, low risk of bias; 2, high risk of bias; ?, unclear
risk of bias. B. Risk of bias graph about each risk of bias item presented as percentages across all included studies.
Saccone. Omega-3 for Prevention of Preterm Birth. Obstet Gynecol 2015.
Fig. 3. Funnel plot for assessing publication bias.
Saccone. Omega-3 for Prevention of Preterm Birth. Obstet Gynecol
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analyses of omega-3 supplementation started before 21
weeks of gestation and in the studies with low risk of
bias. The first subgroup analysis was based on five
trials, of which one was responsible for 85% of
analyzed patients. The second subgroup analysis was
based on three RCTs, of which one was responsible for
Table 1. Descriptive Data of Included Trials
First Author
Study
Location
No. of Patients at
Randomization Intervention* Control*
Primary
Outcome
Olsen4 Denmark 397 (266/131) Eicosapentaenoic acid 1,280 mg
+docosahexaenoic acid 920 mg
No
treatment
Duration of
gestation, birth
weight
Bulstra-
Ramakers5
The
Netherlands
63 (32/31) Eicosapentaenoic acid 3,000 mg
+docosahexaenoic acid not defined
Placebo Gestational
hypertension
Onwude6 United
Kingdom
232 (113/119) Eicosapentaenoic acid 1,620 mg
+docosahexaenoic acid 1,080 mg
Placebo Gestational
hypertension;
SGA
Malcolm7 United
Kingdom
100 (50/50) Docosahexaenoic acid 200 mg Placebo Neonate retinal
function
Sanjuro8 Spain 16 (8/8) Docosahexaenoic acid 200 mg Placebo Biochemical
outcomes
Decsi9 Multicenter 157 (77/80) Docosahexaenoic acid 500 mg Placebo Biochemical
outcomes
Tofail10 Bangladesh 400 (200/200) Eicosapentaenoic acid 1,800 mg
+docosahexaenoic acid 1,200 mg
Placebo Infant’s
development
Makrides11 Australian 2,399 (1,197/1,202) Eicosapentaenoic acid 100 mg
+docosahexaenoic acid 800 mg
Placebo High level of
depressive
symptoms
Escolano-
Margarit12
Multicenter 90 (43/47) Eicosapentaenoic acid 150 mg
+docosahexaenoic acid 500 mg
Placebo Neurologic
assessment
Total — 3,854 (1,986/1,868) — — —
IUGR, intrauterine growth restriction; SGA, small for gestational age.
Data are total n (intervention/control).
* Intervention and control all were administered daily, except in the no-treatment arm of one study.
Table 2. Selected Characteristics and Selected Outcomes of Included Trials
First Author Age Mean (y) Smoking, n
Mean
Gestational
Age at
Randomization
(wk)
Mean
Gestational
Age at
Delivery (d)
Mean
Latency (d)
Olsen4 29 vs 29 88/266 (33.1) vs 43/131
(32.8)
30 vs 30 283 vs 281 73 vs 71
Bulstra-Ramakers5 NA NA 13 vs 13 NA NA
Onwude6 NA 42/113 (37.2) vs 32/119
(26.9)
24 vs 24 266 vs 266 98 vs 98
Malcolm7 NA NA 15 vs 15 280 vs 280 175 vs 175
Sanjuro8 35 vs 31 1/8 (12.5) vs 2/8 (25.0) 26 vs 26 272 vs 275 90 vs 90
Decsi9 NA NA 20 vs 20 NA NA
Tofail10 22 vs 23 NA 25 vs 25 271 vs 274 96 vs 99
Makrides11 29 vs 29 358/1,197 (29.9) vs 407/
1,202 (33.9)
19 vs 19 282 vs 281 149 vs 148
Escolano-Margarit12 30 vs 31 7/43 (16.3) vs 2/47 (4.3) 20 vs 20 272 vs 273 132 vs 133
Total 27 vs 27 550/1,944 (28.3) vs 540/
1,822 (29.7)
23 vs 23 275 vs 274 90 vs 89
Mean difference
(95% CI)
— — 0 wk (20.60 to
0.60)
0.57 d (20.62 to
1.76)
0.83 d (20.86 to
2.52)
NA, not available; CI, confidence interval.
Data are n/N for intervention (%) compared with n/N for control (%) unless otherwise specified.
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83% of analyzed patients. However, in no RCT was
perinatal death the primary outcome.
Four other meta-analyses35 have evaluated the effi-
cacy of omega-3 in prevention of preterm birth. The
first did not include all available RCTs and did not
exclude RCTs with PUFAs as a control. It showed that
omega-3 supplementation may enhance pregnancy
duration and head circumference, but the mean effect
size was small.35 The second meta-analysis included
women with prior preterm birth. It showed no effect
of omega-3 supplementation on preterm birth out-
comes.36 Another meta-analysis included women with
prior preterm birth and also RCTs with PUFAs as
controls. It showed that omega-3 during pregnancy
reduced the rate of preterm birth and increased birth
weight.37 The Cochrane Review on omega-3 supple-
mentation in pregnancy included also RCTs with PU-
FAs as a control and RCTs with prostaglandin
precursor as treatment. It showed a small but consistent
increase in the mean length of gestation.38
One of the strengths of our study is inclusion of
RCT data on omega-3 supplementation during preg-
nancy in a specific population, that is, women
carrying singleton gestations without prior preterm
Table 3. Primary and Secondary Outcomes
First Author
Preterm
Birth at Less
Than 37 Wk of
Gestation
Mean Birth
Weight (g) NICU NEC Sepsis Perinatal Death
Olsen4 9/266 (3.4) vs
6/131 (4.6)
3,571 vs 3,504 NA NA NA 1/266 (0.4) vs
1/131 (0.8)
Bulstra-
Ramakers5
8/32 (25.0) vs
10/31 (32.3)
NA NA NA NA 1/32 (3.1) vs 3/31
(9.7)
Onwude6 22/113 (19.5) vs
19/119 (16.0)
3,033 vs 2,983* NA NA NA 1/113 (0.9) vs
2/119 (1.7)
Malcolm7 0/31 (0) vs 1/32
(3.1)
3,508 vs 3,645 0/31 (0) vs
2/29 (6.9)
NA NA NA
Sanjuro8 NA 3,183 vs 3,385 NA NA NA NA
Decsi9 NA NA NA NA NA NA
Tofail10 30/125 (24.0) vs
27/124 (21.8)
2,700 vs 2,700 NA NA NA 12/159 (7.5) vs
11/165 (6.7)
Makrides11 67/1,197 (5.6) vs
88/1,202 (7.3)
3,475 vs 3,407 NA 1/1,184 (0.1) vs
0/1,177 (0)
3/1,184 (0.3) vs
2/1,177 (0.2)
3/1,197 (0.3) vs
12/1,202 (1.0)
Escolano-
Margarit12
4/43 (9.3) vs 3/47
(6.4)
3,340 vs 3,390 NA NA NA NA
Total 140/1,807 (7.7) vs
154/1,686 (9.1)
3,259 vs 3,288 0/31 (0) vs
2/29 (6.9)
1/1,184 (0.1) vs
0/1,177 (0)
3/1,184 (0.3) vs
2/1,177 (0.2)
18/1,767 (1.0) vs
29/1,648 (1.8)
RR (95% CI) 0.90 (0.72 to
1.11)
Mean difference 27.76
g (95% CI 227.49 to
83.02)*
0.19 (0.01–
3.75)
2.98 (0.12–73.13) 6.96 (0.36–
134.57)
0.61 (0.30–1.24)
NICU, neonatal intensive care unit admission; NEC, necrotizing enterocolitis; NA, not available; RR, relative risk; CI, confidence interval.
Data are n/N for intervention (%) compared with n/N for control (%) unless otherwise specified.
* Birth weight for Onwude 1995 was not included in the analysis because standard deviation was not reported.
Fig. 4. Forest plot for preterm birth at less than 37 weeks of gestation. PTB, preterm birth; M-H, Mantel-Haenszel test; CI,
confidence interval.
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birth. This population represents, in all countries,
usually approximately 90% or more of the pregnant
population. We chose to limit inclusion of studies to
this population because other interventions to prevent
preterm birth have been shown to have different
results in different populations of pregnant women.
For example, progesterone supplementation as well as
cerclage have differing effects depending on prior
preterm birth history or plurality.39,40
Limitations of our study are inherent to the
limitations of the included RCTs. Other limitations
of our meta-analysis are that none of the RCTs
included had preterm birth as the primary outcome
and that the dosage of omega-3 differed somewhat
among studies. The study reports provided no infor-
mation on the use of obstetric interventions to limit
preterm birth, and thus we could not control for any
such interventions. The included studies came from
various regions of the world, so dietary intake of
omega-3 fatty acids may have differed across trials.
Unknown or unmeasured factors not reported in
publications could have modified the observed asso-
ciations. Although no included study mentioned that
women enrolled had a prior preterm birth, this
characteristic was not always reported. Approxi-
mately 62% of the patients in our meta-analysis are
from one trial, which was of high quality.11
According to the Food and Agriculture Organi-
zation of the United Nations41 and the World Health
Organization,42 daily intake of omega-3 supplementa-
tion is recommended during pregnancy. These rec-
ommendations are based on evidence that omega-3
Fig. 5. Forest plot for perinatal death. M-H, Mantel-Haenszel test; CI, confidence interval.
Saccone. Omega-3 for Prevention of Preterm Birth. Obstet Gynecol 2015.
Table 4. Subgroup Analysis Including Trials With Omega-3 Supplementation of Both Eicosapentaenoic
Acid and Docosahexaenoic Acid Daily
First Author Smoking
Mean Gestational
Age at
Randomization (wk)
Preterm Birth at Less
Than 37 Wk of
Gestation
Mean Birth
Weight (g) Perinatal Death
Olsen4 88/266 (33.1) vs
43/131 (32.8)
30 vs 30 9/266 (3.4) vs 6/131
(4.6)
3,571 vs 3,504 1/266 (0.4) vs
1/131 (0.8)
Bulstra-
Ramakers5
NA 13 vs 13 8/32 (25.0) vs 10/31
(32.3)
NA 1/32 (3.1) vs 3/31
(9.7)
Onwude6 42/113 (37.2) vs
32/119 (26.9)
24 vs 24 22/113 (19.5) vs 19/119
(16.0)
3,033 vs 2,983* 1/113 (0.9) vs
2/119 (1.7)
Tofail10 NA 25 vs 25 30/125 (24.0) vs 27/124
(21.8)
2,700 vs 2,700 12/159 (7.5) vs
11/165 (6.7)
Makrides11 358/1,197 (29.9)
vs 407/1,202
(33.9)
19 vs 19 67/1,197 (5.6) vs 88/
1,202 (7.3)
3,475 vs 3,407 3/1,197 (0.3) vs
12/1,202 (1.0)
Escolano-
Margarit12
7/43 (12.3) vs
2/47 (4.3)
20 vs 20 4/43 (9.3) vs 3/47 (6.4) 3,340 vs 3,390 NA
Total 495/1,619 (30.6)
vs 484/1,499
(32.3)
22 vs 22 140/1,776 (7.9) vs 153/
1,654 (9.2)
3,271 vs 3,250 18/1,767 (1.0) vs
29/1,648 (1.8)
RR (95% CI) P5.25 Mean difference 0.12
wk (95% CI 20.48 to
1.23)
0.90 (0.73–1.12) Mean difference 51.18
g (95% CI 12.33–
90.03)*
0.61 (0.30–1.24)
NA, not available; RR, relative risk; CI, confidence interval.
Data are n/N for intervention (%) compared with n/N for control (%) unless otherwise specified.
Bold indicates statistical significance.
* Birth weight for Onwude 1995 was not included in the analysis because standard deviation was not reported.
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Table 5. Subgroup Analysis of Women Randomized Before 21 Weeks of Gestation
First Author Smoking
Mean
Gestational Age
at
Randomization
(wk)
Preterm Birth at
Less Than 37 Wk
of Gestation
Mean Birth
Weight (g) NICU Perinatal Death
Bulstra-
Ramakers5
NA 13 vs 13 8/32 (25.0) vs
10/31 (32.3)
NA NA 1/32 (3.1) vs 3/31
(9.7)
Malcolm7 NA 15 vs 15 0/31 (0) vs 1/32
(3.1)
3,508 vs 3,645 0/31 (0) vs
2/29 (6.9)
NA
Decsi9 NA 20 vs 20 NA NA NA NA
Makrides11 358/1,197 (29.9)
vs 407/1,202
(33.9)
19 vs 19 67/1,197 (5.6) vs
88/1,202 (7.3)
3,475 vs 3,407 NA 3/1,197 (0.3) vs
12/1,202 (1.0)
Escolano-
Margarit12
7/43 (12.3) vs
2/47 (4.3)
20 vs 20 4/43 (9.3) vs 3/47
(6.4)
3,340 vs 3,390 NA NA
Total 365/1,240 (29.4)
vs 409/1,249
(32.7)
18 vs 18 79/1,303 (6.1) vs
102/1,312 (7.8)
3,441 vs 3,480 0/31 (0) vs
2/29 (6.9)
4/1,229 (0.3) vs
15/1,233 (1.2)
RR (95% CI) P5.07 Mean difference
0.05 wk (95%
CI 20.58 to
0.63)
0.78 (0.59–1.03) Mean difference
3.23 g (95% CI
2112.74 to
119.20)
0.19 (0.01–
3.75)
0.27 (0.09–0.80)
NICU, neonatal intensive care unit admission; NA, not available; RR, relative risk; CI, confidence interval.
Data are n/N for intervention (%) compared with n/N for control (%) unless otherwise specified.
Bold indicates statistical significance.
Table 6. Subgroup Analysis of Studies With Low Risk of Bias in All Items According to the Cochrane
Collaboration’s Tool38
First Author Smoking
Mean
Gestational Age
at
Randomization
(wk)
Mean
Gestational
Age at
Delivery (d)
Mean
Latency (d)
Preterm
Birth at Less
Than 37 Wk
of Gestation
Mean Birth
Weight (g)
Perinatal
Death
Olsen4 88/266 (33.1)
vs 43/131
(32.8)
30 vs 30 283 vs 281 73 vs 71 9/266 (3.4) vs
6/131 (4.6)
3,571 vs 3,504 1/266 (0.4) vs
1/131 (0.8)
Makrides11 358/1,197
(29.9) vs
407/1,202
(33.9)
19 vs 19 282 vs 281 149 vs 148 67/1,197 (5.6)
vs 88/1,202
(7.3)
3,475 vs 3,407 3/1,197 (0.3)
vs 12/
1,202 (1.0)
Escolano-
Margarit12
7/43 (12.3) vs
2/47 (4.3)
20 vs 20 272 vs 273 132 vs 133 4/43 (9.3) vs
3/47 (6.4)
3,340 vs 3,390 NA
Total 453/1,506
(30.1) vs
452/1,380
(32.8)
23 vs 23 279 vs 278 118 vs 117 80/1,506 (5.3)
vs 94/1,333
(7.1)
3,462 vs 3,433 4/1,463 (0.3)
vs (1.0)
RR (95% CI) P5.09 Mean difference
0.05 wk (95%
CI 20.78 to
0.95)
Mean
difference
0.89
d (95% CI
20.48 to
1.53)
Mean
difference
0.12
d (95% CI
20.43 to
0.51)
0.78 (0.59–
1.04)
Mean difference
60.66 g (95%
CI 19.78–
101.54)
0.28 (0.09–
0.89)
NA, not available; RR, relative risk; CI, confidence interval.
Data are n/N for intervention (%) compared with n/N for control (%) unless otherwise specified.
Bold indicates statistical significance.
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supplementation during pregnancy is associated with
possible prolongation of pregnancy and other possible
benefits, including prevention of preterm birth.35,37,38
Our meta-analysis shows that omega-3 supplementa-
tion is not associated with prevention of preterm birth
or of neonatal complications. More research is needed
to evaluate whether early omega-3 supplementation
started before 21 weeks of gestation is beneficial.
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